Melanoma Patient Shows Initial Positive Response to Russian Cancer Vaccine
Melanoma Patient Shows Initial Positive Response to Russian Cancer Vaccine
Russia's personalized mRNA cancer vaccine, NeoOncovac, has shown initial positive results in its first patient, a 60-year-old man from the Kursk region with stage 3 skin melanoma.
Key information about the vaccine:
🟠developed by the Gamaleya Center (creators of Sputnik V), along with the National Medical Research Centre of Radiology and Blokhin Oncology Center;
🟠tailored to each patient's tumor molecular profile;
🟠approved for clinical use late in 2025 by the Russian Ministry of Health, marking a milestone in precision oncology;
🟠mRNA-based approach targets neoantigens to activate the immune system against tumors, aligning with global trends in personalized cancer therapies.
Early biological improvements include measurable changes in cytokine production, Alexander Gintsburg, Gamaleya's director, noted. The patient, receiving immunotherapy alongside the vaccine, faces a high risk of progression but shows overall positive clinical evolution; about 10 injections are planned.
A second patient's vaccine synthesis has begun, signaling rapid scaling.
Subscribe to @sputnik_africa
